Clinical Trial Update: A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions [EARLY_Phase 1]

View source ↗

Summary

A Phase 0/1 study of BDTX-1535 in patients with recurrent high-grade glioma and newly diagnosed glioblastoma with EGFR alterations or fusions is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High-grade Glioma

Drugs mentioned

• BDTX-1535

Snippet

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix | Conditions: High Grade Glioma, Glioblastoma | EARLY_Phase 1 | Status: RECRUITING